Related Experiment Video
Updated: Apr 23, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Interleukin 28B genetic polymorphism and hepatitis B virus infection
1Toru Takahashi, Division of Gastroenterology and Hepatology, Uonuma Hospital, Ojiyashi, Niigata 947-0028, Japan.
Interleukin 28B (IL-28B) gene variations impact Hepatitis C treatment outcomes. Research is ongoing to determine if IL-28B genetic polymorphism affects outcomes for chronic Hepatitis B patients treated with interferon.
Area of Science:
- Hepatology
- Virology
- Genetics
Background:
- Interleukin 28B (IL-28B) genetic polymorphism is linked to successful treatment outcomes in chronic Hepatitis C patients receiving pegylated interferon-alfa (PEG-IFN) plus ribavirin.
- The association between IL-28B genetic polymorphism and favorable outcomes in chronic Hepatitis B virus (HBV) infection, such as hepatitis B e antigen (HBeAg) seroconversion or hepatitis B surface antigen (HBsAg) seroclearance, remains unclear.
- Existing studies show conflicting results regarding the impact of IL-28B polymorphism on interferon-based therapies for chronic HBV.
Purpose of the Study:
- To investigate the association between IL-28B genetic polymorphism and treatment outcomes in chronic Hepatitis B patients.
- To clarify the role of IL-28B genetic variations in predicting response to interferon or PEG-IFN therapy for chronic HBV infection.
Main Methods:
- Review of existing literature on IL-28B genetic polymorphism and chronic Hepatitis B treatment outcomes.
- Analysis of data from prospective studies and large cohorts (as suggested for future research).
Main Results:
- A significant association exists between IL-28B genetic polymorphism and sustained virological response in chronic Hepatitis C.
- Evidence for a consistent association between IL-28B genetic polymorphism and favorable outcomes in chronic Hepatitis B treated with interferon or PEG-IFN is currently lacking.
- Some studies suggest a potential association in specific patient populations, but results are not universally consistent.
Conclusions:
- The role of IL-28B genetic polymorphism in predicting the outcome of interferon or PEG-IFN treatment for chronic Hepatitis B requires further investigation.
- More large-scale, prospective studies are necessary to establish a definitive link between IL-28B genetic variations and chronic HBV treatment efficacy.
- Consensus on the predictive value of IL-28B polymorphism for chronic Hepatitis B outcomes is yet to be reached.
More Related Videos
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Hepatitis
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Single Nucleotide Polymorphisms-SNPs
Inhibitors of Viral Protein Synthesis
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase